Sort   by:  
 Page size 
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14634 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (Glucose Tracer)
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14641 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (CAR-T Metabolites)
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14640 | MetaboLights
MetabolomicsmiR-9394b from Lactobacillus paracasei extracellular vesicles targets iNOS to reprogram host NO-ornithine metabolism and ameliorate ulcerative colitis

Background Probiotics have attracted considerable interest for ulcerative colitis (UC); however, their efficacy is highly strain-specific and the underlying molecular mechanisms remain incompletely understood.

Results Accumulating evidence indicates that bacterial extracellular vesicles (BE...

2026-01-23 | MTBLS13753 | MetaboLights
TranscriptomicsMycobacterium tuberculosis TraSH experiment: Growth in wild type C57BL/6J versus iNOS-/- mice
A M. tuberculosis transposon library was used to infect WT and iNOS-/- mice. Surviving mutants were recovered from spleens, genomic DNA was extracted, and labeled probes were synthesized from transposon ends. Probes from each WT mouse were hybridized with probes from a similar iNOS-/- mouse. Two-c...
ORGANISM(S): Mycobacterium tuberculosis 
2009-08-20 | E-GEOD-17706 | biostudies-arrayexpress
TranscriptomicsPlac8-dependent and iNOS-dependent T cell-mediate mechanisms clear Chlamydia muridarum infections from the genital tract
Comparison of two Chlamydia-specific CD4 T cells that are dependent on iNOS to terminate Chlamydia replication in epithelial cells to two Chlamydia-specific CD4 T cells that are iNOS-independent: Chlamydia trachomatis urogenital serovars replicate predominately in epithelial cells lining the reprod...
ORGANISM(S): Mus musculus 
2012-03-14 | E-GEOD-32128 | biostudies-arrayexpress
GenomicsGenome-wide CRISPR knockout screen in Mycobacterium tuberculosis infected macrophages to identify regulators of TNF and iNOS expression
To elucidate the early regulators of inflammation during Mycobacterium tuberculosis infection, we performed a genome-wide CRISPR knockout screen in macrophages to identify genes that influence the induction of TNF and iNOS upon infection. A genome-wide knockout library in murine macrophages was infe...
ORGANISM(S): Mus musculus 
2026-04-29 | E-MTAB-15739 | biostudies-arrayexpress
ProteomicsA new NO-independent immunomodulatory function for iNOS in regulating itaconate production via mitochondrial protein-protein interaction with IRG1
iNOS modulates itaconate metabolism by a novel conformation-dependent protein-protein interaction separate from iNOS-mediated NO generation.
ORGANISM(S): Homo sapiens (Human) 
2026-02-20 | PXD048712 | Pride
Macrophages Tca cycle by cis-aconitate decarboxylase Inos and irg1 
GenomicsKSHV-induced iNOS in Kaposi’s Sarcoma tumors and mouse model
KSHV-induced iNOS in Kaposi’s Sarcoma tumors and mouse model
PRJNA922466 | ENA
ProteomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
ORGANISM(S): Mus musculus (Mouse) 
2026-05-30 | PXD079073 | Pride
Macrophages B cell lymphoma Interferon Inos Chimeric antigen receptor t cell 
Sort   by:  
 Page size